Shares of Gritstone bio, Inc. (Nasdaq: GRTS) soared over 40% in after-hours trading  following the company's announcement of an up to $433 million contract awarded by the Biomedical Advanced Research and Development Authority (BARDA). The contract is part of the 'Project NextGen' initiative by the U.S. Department of Health and Human Services (HHS)

Gritstone bio will conduct a Phase 2b comparative study with 10,000 participants to evaluate the efficacy, safety, and immunogenicity of its self-amplifying mRNA (samRNA) vaccine candidate, which includes Spike and other viral targets. This study will compare the Gritstone vaccine with an approved COVID-19 vaccine.

$GRTS was trading at $1.78 in the extended session, reflecting an increase of $0.59 (+49.57%).

In a similar vein, shares of Peloton Interactive, Inc. (Nasdaq: PTON) witnessed a surge of more than 10% after the closing bell following a significant announcement. The company has entered into a five-year strategic global partnership with Lululemon Athletica Inc. (Nasdaq: LULU).

As part of the deal, lululemon will become Peloton's primary athletic apparel partner, while Peloton will take on the exclusive role of providing digital fitness content to lululemon. Beginning in early 2024, Peloton will also be responsible for creating all content for lululemon Studio.

In after-hours, $PTON was trading at $5.46, up $0.81 (+17.42%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)